Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Oncology

  • 1,527 Articles
  • 14 Posts
  • ← Previous
  • 1
  • 2
  • 3
  • …
  • 152
  • 153
  • Next →
Conserved programmed cell death patterns associate with subtype-specific therapeutic response across multiple cancer types
Zi-Wei Huang, Zi-Han Wang, Yi Liu, Jia-Yi Shen, Yan-Ling Wu, Zi-An Fang, Dong-Hong Wu, Yi-Zhe Cheng, Jing-Jing Zhang, Xiong Zou, Jun Ma, Jiawei Lv, Shuang Wang, Yu-Pei Chen
Zi-Wei Huang, Zi-Han Wang, Yi Liu, Jia-Yi Shen, Yan-Ling Wu, Zi-An Fang, Dong-Hong Wu, Yi-Zhe Cheng, Jing-Jing Zhang, Xiong Zou, Jun Ma, Jiawei Lv, Shuang Wang, Yu-Pei Chen
View: Text | PDF

Conserved programmed cell death patterns associate with subtype-specific therapeutic response across multiple cancer types

  • Text
  • PDF
Abstract

BACKGROUND. Molecular subtyping may offer a promising path toward a unified framework for precision oncology. We sought to characterize the patterns of programmed cell death (PCD), a pivotal cellular process shaping both intrinsic tumor malignancy and the tumor microenvironment, to better understand tumor heterogeneity. METHODS. We performed integrative multi-cohort transcriptomic analyses encompassing four canonical PCD modes across multiple cancer types. We identified PCD subtypes using nonnegative matrix factorization (NMF), characterized their molecular features and clinical relevance, and developed a streamlined 20-gene classifier to facilitate subtype assignment. RESULTS. We identified five conserved PCD subtypes with distinct genomic alterations, cellular stresses, malignant traits, prognostic outcomes, and immune landscapes. In the immunotherapy setting, PCD subtypes were associated with distinct outcomes across multiple cancer types, with the pyroptosis-dominant (PCD-P) subtype showing the most favorable outcomes. The 20-gene classifier showed good discriminatory performance across independent cohorts. Finally, we proposed candidate subtype-specific therapeutic strategies. CONCLUSION. This study establishes a comprehensive framework for characterizing PCD patterns in cancer, laying the groundwork for biomarker discovery and rational therapeutic design that warrant future evaluation of efficacy and toxicity. FUNDING. National Key R&D Program of China; National Natural Science Foundation of China; Fundamental Research Funds for the Central Universities, Sun Yat-sen University; HE Science Foundation; Young Talents Program of Sun Yat-sen University Cancer Center; Academician Workstation of Jun Ma; Specific Research Fund of the Innovation Platform for Academicians of Hainan Province; Shenzhen Medical Research Fund; Guangdong Basic and Applied Basic Research Foundation.

Authors

Zi-Wei Huang, Zi-Han Wang, Yi Liu, Jia-Yi Shen, Yan-Ling Wu, Zi-An Fang, Dong-Hong Wu, Yi-Zhe Cheng, Jing-Jing Zhang, Xiong Zou, Jun Ma, Jiawei Lv, Shuang Wang, Yu-Pei Chen

×

Logic-gated T cell engager with mutant IL-2 potentiates antitumor responses without cytotoxicity in solid tumor models
Shijie Li, Nan Li, Xiangming Liu, Yueqi Cai, Mukai Wang, Huimin Wang, Yang-Xin Fu, Zaopeng Yang
Shijie Li, Nan Li, Xiangming Liu, Yueqi Cai, Mukai Wang, Huimin Wang, Yang-Xin Fu, Zaopeng Yang
View: Text | PDF

Logic-gated T cell engager with mutant IL-2 potentiates antitumor responses without cytotoxicity in solid tumor models

  • Text
  • PDF
Abstract

T cell engagers (TCEs) have achieved transformative success in B cell malignancies but show limited efficacy in solid tumors with severe toxicity. We propose that TCR signaling without IL-2 might limit the function of tumor-infiltrating lymphocytes (TILs). Here, we showed that insufficient IL-2 signaling is a key bottleneck for sustaining TCE-induced T cell function. Although exogenous IL-2 enhances TCE efficacy, its systemic administration causes more severe toxicity. We engineered a protease-activatable dual-variable domain (DVD) as a pro-antibody to reduce αCD3 off-tumor toxicity. Furthermore, we designed 3 additional mutations for IL-2 (3E) with markedly reduced receptor affinity, which remained inactive in the periphery. By coengineering the DVD and 3E into a single pro-drug molecule (DVD-3E), we achieved conditional IL-2 and TCR cosignaling strictly dependent on cis CD3 engagement within the tumor microenvironment (TME) upon protease cleavage. This logic-gated design restricted both TCE and cytokine activity to the TME, enabling potent antitumor responses without systemic toxicity. Mechanistically, DVD-3E enhanced not only the persistence and effector function of preexisting intratumoral T cells but also expanded TCF1+ TILs, mitigating exhaustion and enabling durable systemic immunity. These findings define a new design principle for logic-gated TCEs that achieve a favorable balance between efficacy and safety, offering a strategy to overcome current therapeutic resistance.

Authors

Shijie Li, Nan Li, Xiangming Liu, Yueqi Cai, Mukai Wang, Huimin Wang, Yang-Xin Fu, Zaopeng Yang

×

METTL8 orchestrates TFH cell differentiation through m³C-mediated TCF1 regulation in infection and cancer models
Jiaxi Song, Dan Cui, Jiabao Wang, Xuewei Qi, Jiaxin Ma, Haoyu Yu, Qing Liu, Jing Yang, Tengfei Hu, Xu Han, Handong Ma, Rentao Yu, Ying Dai, Xiaona Zhang, Qunfa Cao, Xiaoyuan Song, Bofeng Li, Lilin Ye, Hua Wang, Qizhao Huang, Jia Li, Fengyin Li
Jiaxi Song, Dan Cui, Jiabao Wang, Xuewei Qi, Jiaxin Ma, Haoyu Yu, Qing Liu, Jing Yang, Tengfei Hu, Xu Han, Handong Ma, Rentao Yu, Ying Dai, Xiaona Zhang, Qunfa Cao, Xiaoyuan Song, Bofeng Li, Lilin Ye, Hua Wang, Qizhao Huang, Jia Li, Fengyin Li
View: Text | PDF

METTL8 orchestrates TFH cell differentiation through m³C-mediated TCF1 regulation in infection and cancer models

  • Text
  • PDF
Abstract

T follicular helper (TFH) cells are critical for humoral immunity against infections and correlate with immunotherapy efficacy, whereas immune checkpoint inhibitor therapy can drive their aberrant expansion, underscoring the need to understand the regulators controlling TFH cell fate. However, the epitranscriptomic regulation of their differentiation remains poorly understood. Here, we identify the 3-methylcytosine (m³C) methyltransferase METTL8 as a key regulator of TFH cell differentiation in both viral infection and cancer. METTL8 was preferentially expressed in CXCL13hi TFH cells, and its deficiency impaired TFH differentiation and germinal center responses in the lymphocytic choriomeningitis virus infection model and following anti–PD-1 immunotherapy in tumor models. Mechanistically, METTL8 exerted dual functions: it bound and stabilized Tcf7 mRNA through m³C modification, and it interacted with TCF1 protein to regulate chromatin accessibility and 3D genome organization at key TFH-associated loci, including Cxcr5 and Il6ra. Notably, ginkgolic acid treatment suppressed TFH responses without compromising the antitumor efficacy of anti–PD-1 therapy, an effect associated with METTL8. Collectively, our findings identify METTL8 as an epitranscriptomic regulator linked to RNA modification, TCF1-associated transcriptional control, and chromatin architecture during TFH differentiation and suggest that modulation of this pathway may provide a strategy to tune TFH-driven immune responses.

Authors

Jiaxi Song, Dan Cui, Jiabao Wang, Xuewei Qi, Jiaxin Ma, Haoyu Yu, Qing Liu, Jing Yang, Tengfei Hu, Xu Han, Handong Ma, Rentao Yu, Ying Dai, Xiaona Zhang, Qunfa Cao, Xiaoyuan Song, Bofeng Li, Lilin Ye, Hua Wang, Qizhao Huang, Jia Li, Fengyin Li

×

ATRX loss predicts poor outcomes and sensitizes to TEAD inhibition in soft tissue sarcomas
Ryan A. Denu, Anand K. Singh, Yingda Jiang, Zhao Zheng, Davis R. Ingram, Khalida M. Wani, Rossana Lazcano, Madison P. Ginn, Kumaren Anand, Bishal K. Singh, Jackson C. Ballard, Veena Kochat, Biji Chatterjee, William Padron, Sharon M. Landers, Angela D. Bhalla, Asha S. Multani, Sharvari Dharmaiah, Prit Benny Malgulwar, Yiming Cai, Jun Yao, Heather Lin, Jason T. Huse, Haoqiang Ying, Emily Z. Keung, Wei-Lien Wang, Anthony P. Conley, Shreyaskumar Patel, Neeta Somaiah, Ahsan S. Farooqi, Alexander J. Lazar, Elise F. Nassif Haddad, Keila E. Torres, Kunal Rai
Ryan A. Denu, Anand K. Singh, Yingda Jiang, Zhao Zheng, Davis R. Ingram, Khalida M. Wani, Rossana Lazcano, Madison P. Ginn, Kumaren Anand, Bishal K. Singh, Jackson C. Ballard, Veena Kochat, Biji Chatterjee, William Padron, Sharon M. Landers, Angela D. Bhalla, Asha S. Multani, Sharvari Dharmaiah, Prit Benny Malgulwar, Yiming Cai, Jun Yao, Heather Lin, Jason T. Huse, Haoqiang Ying, Emily Z. Keung, Wei-Lien Wang, Anthony P. Conley, Shreyaskumar Patel, Neeta Somaiah, Ahsan S. Farooqi, Alexander J. Lazar, Elise F. Nassif Haddad, Keila E. Torres, Kunal Rai
View: Text | PDF

ATRX loss predicts poor outcomes and sensitizes to TEAD inhibition in soft tissue sarcomas

  • Text
  • PDF
Abstract

ATRX is one of the most frequently altered genes in sarcoma and encodes an ATP-dependent chromatin remodeler implicated in maintaining heterochromatin. However, ATRX alterations have not been leveraged for sarcoma treatment. We observed loss of ATRX protein in 14% of soft tissue leiomyosarcoma (STLMS, n =127), 53% of uterine leiomyosarcoma (ULMS, n = 95), 37% of undifferentiated pleomorphic sarcoma (UPS, n = 82), and 8% of dedifferentiated liposarcoma (DDLPS, n = 84). ATRX loss was associated with significantly worse outcomes in ULMS, UPS, and DDLPS. ATRX knockout in sarcoma cells increased proliferation in cooperation with TP53 deletion, chromatin remodeling, and enrichment of PRDM4 and NFIX transcription factor motifs. PRDM4 and NFIX knockdown in ATRX-mutant sarcoma lines resulted in reduced proliferation and invasion, suggesting an epistatic relationship. Consistent with the known and re-demonstrated functional relationship between PRMD4 and YAP1, ATRX loss activated YAP1-TEAD signaling, and ATRX-deficient cells and sarcoma xenografts were more sensitive to the TEAD inhibitors VT103 and IAG933. Overall, our results identify ATRX loss as a prognostic factor of worse outcomes, implicate the ATRX-PRDM4-YAP1-TEAD axis as an underlying mechanism, and suggest use of TEAD inhibition as a potential therapeutic strategy for ATRX-deficient sarcomas.

Authors

Ryan A. Denu, Anand K. Singh, Yingda Jiang, Zhao Zheng, Davis R. Ingram, Khalida M. Wani, Rossana Lazcano, Madison P. Ginn, Kumaren Anand, Bishal K. Singh, Jackson C. Ballard, Veena Kochat, Biji Chatterjee, William Padron, Sharon M. Landers, Angela D. Bhalla, Asha S. Multani, Sharvari Dharmaiah, Prit Benny Malgulwar, Yiming Cai, Jun Yao, Heather Lin, Jason T. Huse, Haoqiang Ying, Emily Z. Keung, Wei-Lien Wang, Anthony P. Conley, Shreyaskumar Patel, Neeta Somaiah, Ahsan S. Farooqi, Alexander J. Lazar, Elise F. Nassif Haddad, Keila E. Torres, Kunal Rai

×

Biological sex-dependent hormonal signaling and metabolomic profiles in obesity alter tumor microenvironment and immunotherapy outcomes
Logan V. Vick, Spencer R. Rosario, Ziming Wang, Craig Collins, Lam T. Khuat, Yatian Yang, Michael K. Sheng, Wahed A. Firoz, Ryan N. Nielsen, Yao-Hui Sun, Aryana M. Razmara, Hossein Borghaei, Emmanuel S. Antonarakis, Andrew Elliott, Nishant Gandhi, Raid Aljumaily, Sami Ibrahimi, Michael Machiorlatti, Sara K. Vesely, Shuchi Gulati, Sarbajit Mukherjee, Robert J. Canter, Sean J. Judge, Arta M. Monjazeb, William J. Murphy
Logan V. Vick, Spencer R. Rosario, Ziming Wang, Craig Collins, Lam T. Khuat, Yatian Yang, Michael K. Sheng, Wahed A. Firoz, Ryan N. Nielsen, Yao-Hui Sun, Aryana M. Razmara, Hossein Borghaei, Emmanuel S. Antonarakis, Andrew Elliott, Nishant Gandhi, Raid Aljumaily, Sami Ibrahimi, Michael Machiorlatti, Sara K. Vesely, Shuchi Gulati, Sarbajit Mukherjee, Robert J. Canter, Sean J. Judge, Arta M. Monjazeb, William J. Murphy
View: Text | PDF

Biological sex-dependent hormonal signaling and metabolomic profiles in obesity alter tumor microenvironment and immunotherapy outcomes

  • Text
  • PDF
Abstract

Commonly viewed as a negative prognostic factor in cancer, obesity is associated with improved responses to cancer immunotherapy using immune checkpoint inhibitors (ICIs). Although data suggest a sexual dimorphism influencing the effects of obesity on immunotherapy responses, to our knowledge, the intersection of sex and obesity on immunotherapy requires further exploration. We demonstrate, in a pan-cancer analysis stratified by sex and BMI, that obesity (BMI ≥ 30) is associated with improved survival after ICI only in male patients. In preclinical models of diet-induced obesity (DIO), we observed that only DIO male tumor-bearing mice responded better to ICI. The differential effect of sex on outcomes was associated with alterations in the tumor microenvironment where DIO female mice demonstrated increased tumor-associated macrophages skewed toward a M2 phenotype. Ovariectomy of DIO female mice reduced M2 polarization and increased anti-tumor immune responses including increases in tumor-infiltrating T cells following ICI. Metabolomic analysis of DIO mice demonstrated distinct profiles base on sex. Re-stratification of female cancer patients revealed that obesity was associated with improved outcome, but only in post-menopausal (age ≥ 55) patients. We identify that the immunotherapy “obesity paradox” is sex-dependent and that hormonal and metabolomic status modulates the influence of obesity on ICIs.

Authors

Logan V. Vick, Spencer R. Rosario, Ziming Wang, Craig Collins, Lam T. Khuat, Yatian Yang, Michael K. Sheng, Wahed A. Firoz, Ryan N. Nielsen, Yao-Hui Sun, Aryana M. Razmara, Hossein Borghaei, Emmanuel S. Antonarakis, Andrew Elliott, Nishant Gandhi, Raid Aljumaily, Sami Ibrahimi, Michael Machiorlatti, Sara K. Vesely, Shuchi Gulati, Sarbajit Mukherjee, Robert J. Canter, Sean J. Judge, Arta M. Monjazeb, William J. Murphy

×

Nuclear cGAS governs transcription to control lipid metabolism, tumor growth, and therapy response
Yu Deng, Matthew J. Niederhuber, Zhichuan Zhu, Austin J. Hepperla, Le Yu, Quentin Hahn, Joshua Hartsell, Tooba Rashid, Piotr A. Mieczkowski, Hemant Kelkar, Jeremy M. Simon, Yanqiong Zhang, Alessandra Livraghi-Butrico, Meredith J. Zeller, Joseph G.C. Kennedy, Jazmin F. DePriest, Jiong Li, Yan Zhang, Xing Qiu, H. Ümit Kaniskan, Jian Jin, Corbin D. Jones, Laura E. Herring, Douglas H. Phanstiel, Xiaojing Liu, Jesse R. Raab, Brian D. Strahl, Pengda Liu
Yu Deng, Matthew J. Niederhuber, Zhichuan Zhu, Austin J. Hepperla, Le Yu, Quentin Hahn, Joshua Hartsell, Tooba Rashid, Piotr A. Mieczkowski, Hemant Kelkar, Jeremy M. Simon, Yanqiong Zhang, Alessandra Livraghi-Butrico, Meredith J. Zeller, Joseph G.C. Kennedy, Jazmin F. DePriest, Jiong Li, Yan Zhang, Xing Qiu, H. Ümit Kaniskan, Jian Jin, Corbin D. Jones, Laura E. Herring, Douglas H. Phanstiel, Xiaojing Liu, Jesse R. Raab, Brian D. Strahl, Pengda Liu
View: Text | PDF

Nuclear cGAS governs transcription to control lipid metabolism, tumor growth, and therapy response

  • Text
  • PDF
Abstract

Cyclic GMP-AMP synthase (cGAS) is a cytosolic DNA sensor critical for host defense against microbial infections. To prevent aberrant activation, nuclear cGAS is restrained by nucleosome tethering or by barrier-to-autointegration factor–mediated restriction of its access to DNA. However, its physiological roles beyond enzymatic suppression in the nucleus remain poorly understood. Here, we present a genome-wide map of cGAS chromatin localization in human cells and unexpectedly find its binding beyond nucleosome tethering, where cGAS is recruited to chromatin by AP-1 transcription factors via a potentially previously uncharacterized transactivation domain. Integrated CUT&RUN, RNA-seq, and metabolomics analyses reveal that cGAS transcriptionally regulates cholesterol homeostasis. Mechanistically, cGAS promotes LGALS3 transcription, which inhibits ACAA2 activity to suppress fatty acid oxidation and acetyl-CoA production, thereby lowering intracellular cholesterol levels. Reduced cholesterol lowers plasma membrane phosphatidylinositol [3,4,5] triphosphate [PI(3,4,5)P3] levels and decreases mTOR complex 2 (mTORC2) activation. In contrast, cGAS depletion results in cholesterol accumulation and elevated PI(3,4,5)P3, driving mTORC2/Akt signaling, promoting xenografted tumor growth, and conferring resistance to DNA-damaging agents. In vivo, the elevated hepatic cholesterol levels observed in cGas–/– mice were largely reversed by inhibition of Akt but not STING, whereas cGAS deficiency had minimal effects on lung physiology. Collectively, our findings uncover an unexpected role for nuclear cGAS in orchestrating a transcriptional program that links lipid metabolism to cell proliferation, stress response, and cholesterol homeostasis in liver.

Authors

Yu Deng, Matthew J. Niederhuber, Zhichuan Zhu, Austin J. Hepperla, Le Yu, Quentin Hahn, Joshua Hartsell, Tooba Rashid, Piotr A. Mieczkowski, Hemant Kelkar, Jeremy M. Simon, Yanqiong Zhang, Alessandra Livraghi-Butrico, Meredith J. Zeller, Joseph G.C. Kennedy, Jazmin F. DePriest, Jiong Li, Yan Zhang, Xing Qiu, H. Ümit Kaniskan, Jian Jin, Corbin D. Jones, Laura E. Herring, Douglas H. Phanstiel, Xiaojing Liu, Jesse R. Raab, Brian D. Strahl, Pengda Liu

×

Neoadjuvant PD-L1/TGF-β blockade can rapidly disrupt the tumor stroma in head and neck cancer patients
Caroline Hoffmann, Jan-Timon Werle, Philémon Sirven, Mamy Andrianteranagna, Jocelyn Gal, Wiem Lassoued, Jerzy Klijanienko, Jeremy Mesple, Benjamin Demaille, Abdenour Abbas, Valentine Gauthier, Kyra J.E. Borgman, Isabelle Puisieux, Serena Janho dit Hreich, Olivier Choussy, Gregoire Marret, Sonia Lameiras, Nathalie Badois, Antoine Dubray-Vautrin, Gilles Dolivet, Lionnel Geoffrois, Renaud Leclère, Wail Zeitouni, Noemie Robil, Jane Merlevede, Altynbek Zhubanchaliyev, Maud Kamal, Ivan Bieche, Laure Monard, Clotilde Simon, Delphine Louis, Clint T. Allen, Arun Rajan, James L. Gulley, Maude Guillot-Delost, Christophe Le Tourneau, Hélène Salmon
Caroline Hoffmann, Jan-Timon Werle, Philémon Sirven, Mamy Andrianteranagna, Jocelyn Gal, Wiem Lassoued, Jerzy Klijanienko, Jeremy Mesple, Benjamin Demaille, Abdenour Abbas, Valentine Gauthier, Kyra J.E. Borgman, Isabelle Puisieux, Serena Janho dit Hreich, Olivier Choussy, Gregoire Marret, Sonia Lameiras, Nathalie Badois, Antoine Dubray-Vautrin, Gilles Dolivet, Lionnel Geoffrois, Renaud Leclère, Wail Zeitouni, Noemie Robil, Jane Merlevede, Altynbek Zhubanchaliyev, Maud Kamal, Ivan Bieche, Laure Monard, Clotilde Simon, Delphine Louis, Clint T. Allen, Arun Rajan, James L. Gulley, Maude Guillot-Delost, Christophe Le Tourneau, Hélène Salmon
View: Text | PDF

Neoadjuvant PD-L1/TGF-β blockade can rapidly disrupt the tumor stroma in head and neck cancer patients

  • Text
  • PDF
Abstract

BACKGROUND TGF-β drives fibroblast activation in cancer and is a resistance biomarker to PD-1/PD-L1 blockade.METHODS Focusing on the tumor stroma, we characterized the impact of neoadjuvant treatment with bintrafusp alfa (BA), a dual PD-L1 and TGF-β inhibitor, in a window-of-opportunity study with 6 patients with head and neck squamous cell carcinoma (HNSCC). Tumor biopsies before treatment and 3 weeks after therapy were analyzed using scRNA-seq, imaging, and spatial transcriptomics.RESULTS After treatment, we observed significantly decreased levels of activated LRRC15+ cancer-associated fibroblasts (CAFs), remodeled stromal architecture with reduced collagen I and XII content, and increased CD8+ T cell infiltration in immune-excluded tumors. These changes were independently confirmed in an additional neoadjuvant BA-treated cohort of 6 patients with HNSCC. The drastic CAF and stromal compartment reduction observed indicated a fibroblast depletion rather than a fibroblast polarization shift.CONCLUSION While our final clinical cohort does not allow assessment of the treatment effect, this study demonstrated that targeting TGF-β in patients can disrupt the tumor stroma within a short time frame. Further trials and novel biomarkers are now needed to select patients who could benefit.TRIAL REGISTRATION ClinicalTrials.gov NCT04428047.FUNDING Merck KGaA, ARC Emerging Leaders in Oncology, ANR-10-IDEX-0001-02 PSL, Centre d’Investigation Clinique IGR-Curie 1428, Site de Recherche Intégrée sur le Cancer (INCa-DGOS-Inserm-ITMO cancer_18000), French Government “Investissements d’Avenir” program, France 2030 program, Fondation pour la Recherche Médicale, Marie Skłodowska-Curie grant agreement 847718, Cooperative Research and Development Agreement with EMD Serono, and NIH (ZIA BC 010666).

Authors

Caroline Hoffmann, Jan-Timon Werle, Philémon Sirven, Mamy Andrianteranagna, Jocelyn Gal, Wiem Lassoued, Jerzy Klijanienko, Jeremy Mesple, Benjamin Demaille, Abdenour Abbas, Valentine Gauthier, Kyra J.E. Borgman, Isabelle Puisieux, Serena Janho dit Hreich, Olivier Choussy, Gregoire Marret, Sonia Lameiras, Nathalie Badois, Antoine Dubray-Vautrin, Gilles Dolivet, Lionnel Geoffrois, Renaud Leclère, Wail Zeitouni, Noemie Robil, Jane Merlevede, Altynbek Zhubanchaliyev, Maud Kamal, Ivan Bieche, Laure Monard, Clotilde Simon, Delphine Louis, Clint T. Allen, Arun Rajan, James L. Gulley, Maude Guillot-Delost, Christophe Le Tourneau, Hélène Salmon

×

JAK1/2 inhibition promotes aggressive cutaneous carcinogenesis through COT kinase–mediated alternative MAPK pathway activation
Hélène Pasquer, Antoine Forget, Maxime Battistella, Raphael Marie, Léa Provent, Barouyr Baroudjian, Emmanuelle Latour, Cécile Culeux, Blandine Roux, Khansa Saadallah, Amandine Gouverneur, Maxime Demourgues, Fanélie Jouenne, Jérôme Lambert, Bérangère Lombard, Damarys Loew, Sophie Tartare-Deckert, Lionel Adès, Emmanuel Raffoux, Bruno Cassinat, Juliette Soret-Dulphy, Pernelle Noize, Samia Mourah, Camille Lobry, Jean-Jacques Kiladjian, Alexandre Puissant, Céleste Lebbé, Lina Benajiba
Hélène Pasquer, Antoine Forget, Maxime Battistella, Raphael Marie, Léa Provent, Barouyr Baroudjian, Emmanuelle Latour, Cécile Culeux, Blandine Roux, Khansa Saadallah, Amandine Gouverneur, Maxime Demourgues, Fanélie Jouenne, Jérôme Lambert, Bérangère Lombard, Damarys Loew, Sophie Tartare-Deckert, Lionel Adès, Emmanuel Raffoux, Bruno Cassinat, Juliette Soret-Dulphy, Pernelle Noize, Samia Mourah, Camille Lobry, Jean-Jacques Kiladjian, Alexandre Puissant, Céleste Lebbé, Lina Benajiba
View: Text | PDF

JAK1/2 inhibition promotes aggressive cutaneous carcinogenesis through COT kinase–mediated alternative MAPK pathway activation

  • Text
  • PDF
Abstract

Secondary malignancies are the most feared adverse effects of cancer therapies. In this study, we explored the cutaneous oncogenic effects of the JAK inhibitor ruxolitinib. First, we demonstrated an epidemiological association between ruxolitinib exposure and development of aggressive cutaneous squamous cell carcinoma (cSCC) by analyzing international pharmacovigilance data and conducting a large cohort study. We next demonstrated the causal link between ruxolitinib treatment and cSCC development using in vitro and in vivo models. Mechanistically, we revealed that ruxolitinib induces transformation of premalignant keratinocytes by activating the MAPK pathway. This effect is mostly driven by JAK2 inhibition, suggesting a pharmacological class effect. To unravel the mechanistic underpinnings of ruxolitinib-induced MAPK activation, we then applied a phosphoproteomic approach. Alternative MAPK signaling downstream of the kinase COT was pinpointed as the main activator of the pathway in this context. The central role of COT was functionally validated using chemical inhibition, genetic impairment, and inactivated COT mutant expression. Indeed, impairment of COT rescued the pro-oncogenic effect of ruxolitinib. Finally, we determined using a combination of epidemiological, in vitro, and in vivo studies that ruxolitinib-mediated oncogenic effects also result in an increased risk of melanoma, suggesting that the uncovered cellular signaling mechanism might be extrapolated to other cancers with a high dependency on the MAPK pathway.

Authors

Hélène Pasquer, Antoine Forget, Maxime Battistella, Raphael Marie, Léa Provent, Barouyr Baroudjian, Emmanuelle Latour, Cécile Culeux, Blandine Roux, Khansa Saadallah, Amandine Gouverneur, Maxime Demourgues, Fanélie Jouenne, Jérôme Lambert, Bérangère Lombard, Damarys Loew, Sophie Tartare-Deckert, Lionel Adès, Emmanuel Raffoux, Bruno Cassinat, Juliette Soret-Dulphy, Pernelle Noize, Samia Mourah, Camille Lobry, Jean-Jacques Kiladjian, Alexandre Puissant, Céleste Lebbé, Lina Benajiba

×

TARBP2 facilitates renal cell carcinoma immune escape by suppressing 53BP1 phase separation to upregulate B7-H3
Minyu Chen, Mingjie Lin, Jiangquan Zhu, Kezhi Liu, Guannan Shu, Zhuting Tong, Mi Zhou, Liangmin Fu, Taowei Yang, Yihui Pan, Xinwei Zhou, Jinchen Luo, Wuyuan Liao, Qihao Li, Lican Liao, Hansen Lin, Kangbo Huang, Lizhen Zhang, Wei Chen, Junhang Luo, Jiaxing Zhang
Minyu Chen, Mingjie Lin, Jiangquan Zhu, Kezhi Liu, Guannan Shu, Zhuting Tong, Mi Zhou, Liangmin Fu, Taowei Yang, Yihui Pan, Xinwei Zhou, Jinchen Luo, Wuyuan Liao, Qihao Li, Lican Liao, Hansen Lin, Kangbo Huang, Lizhen Zhang, Wei Chen, Junhang Luo, Jiaxing Zhang
View: Text | PDF

TARBP2 facilitates renal cell carcinoma immune escape by suppressing 53BP1 phase separation to upregulate B7-H3

  • Text
  • PDF
Abstract

Renal cell carcinoma (RCC) harbors an immunosuppressive tumor microenvironment that facilitates immune evasion and resistance to immune checkpoint blockade (ICB). However, the factors driving immune escape in RCC remain incompletely understood. In this study, transactivation response RNA-binding protein 2 (TARBP2) was identified as a critical regulator of the immune checkpoint molecule B7-H3. Elevated TARBP2 expression was associated with poor prognosis and ICB resistance in patients with RCC. Functionally, TARBP2 in RCC cells suppressed the intratumoral accumulation and cytotoxicity of T cells, particularly NK cells, thereby promoting immune escape. Mechanistically, nuclear TARBP2 interacted with p53-binding protein 1 (53BP1), inhibiting 53BP1 phase separation and subsequent p53 activation, thereby augmenting B7-H3 transcription. Furthermore, TARBP2 inhibition significantly enhanced ICB efficacy when combined with adoptive NK cell therapy. Collectively, these findings establish TARBP2 as a key mediator of immune evasion in RCC and a promising therapeutic target for overcoming ICB resistance.

Authors

Minyu Chen, Mingjie Lin, Jiangquan Zhu, Kezhi Liu, Guannan Shu, Zhuting Tong, Mi Zhou, Liangmin Fu, Taowei Yang, Yihui Pan, Xinwei Zhou, Jinchen Luo, Wuyuan Liao, Qihao Li, Lican Liao, Hansen Lin, Kangbo Huang, Lizhen Zhang, Wei Chen, Junhang Luo, Jiaxing Zhang

×

Targeting N-acetyltransferase 10 reprograms Treg function to enhance anti–PD-1 immunotherapy sensitivity in murine lung tumors
Xuewei Qi, Dan Cui, Xiao Li, Wenfan Fu, Handong Ma, Wenting Guo, Jiabao Wang, Jiaxi Song, Jiaxin Ma, Jing Yang, Haoyu Yu, Yuting Hong, Qian Wang, Susu Luo, Jia Wang, Baixing Wu, Shanshan Li, Hao Cheng, Min Cheng, Bin Li, Kaiming Zhang, Jia Li, Fengyin Li
Xuewei Qi, Dan Cui, Xiao Li, Wenfan Fu, Handong Ma, Wenting Guo, Jiabao Wang, Jiaxi Song, Jiaxin Ma, Jing Yang, Haoyu Yu, Yuting Hong, Qian Wang, Susu Luo, Jia Wang, Baixing Wu, Shanshan Li, Hao Cheng, Min Cheng, Bin Li, Kaiming Zhang, Jia Li, Fengyin Li
View: Text | PDF

Targeting N-acetyltransferase 10 reprograms Treg function to enhance anti–PD-1 immunotherapy sensitivity in murine lung tumors

  • Text
  • PDF
Abstract

A significant challenge for improving the efficacy of immune checkpoint blockade (ICB) therapy is the concurrent activation of Tregs, which can dampen antitumor responses. Thus, elucidating the mechanisms that maintain Treg-suppressive function within the tumor microenvironment is critical. Here, we identified an accumulation of N-acetyltransferase 10–modified (NAT10-modified) RNA, particularly in NAT10+FOXP3+ Tregs, in human non–small cell lung cancer. Genetic ablation of Nat10 in tumor-infiltrating (TI) Tregs, or pharmacological inhibition of NAT10 expression, significantly reduced the PD-1+ Treg/CD8+ T cell ratio. These effects were accompanied by an increase in IFN-γ+ Tregs, a reduction in the immunosuppressive activity of Tregs, and inhibition of tumor progression. Mechanistically, NAT10 promotes TI Treg infiltration and activation independently of its RNA-modifying function by directly interacting with FOXP3 and chromatin, modulating local 3D chromatin contacts. Combined administration of anti–PD-1 antibodies and a NAT10 inhibitor further impaired TI Treg–mediated immunosuppression, leading to enhanced tumor control. Our findings demonstrate that NAT10 is a key regulator of TI Treg fragility and function and that its inhibition may enhance the therapeutic efficacy of ICB.

Authors

Xuewei Qi, Dan Cui, Xiao Li, Wenfan Fu, Handong Ma, Wenting Guo, Jiabao Wang, Jiaxi Song, Jiaxin Ma, Jing Yang, Haoyu Yu, Yuting Hong, Qian Wang, Susu Luo, Jia Wang, Baixing Wu, Shanshan Li, Hao Cheng, Min Cheng, Bin Li, Kaiming Zhang, Jia Li, Fengyin Li

×
  • ← Previous
  • 1
  • 2
  • 3
  • …
  • 152
  • 153
  • Next →
  • ← Previous
  • 1
  • 2
  • Next →
E2F8 keeps liver cancer at bay
Alain de Bruin, Gustavo Leone, and colleagues find that the E2F8-mediated transcriptional repression in the developing liver suppresses hepatocellular carcinoma later in life …
Published July 25, 2016
Scientific Show StopperOncology

AIDing and abetting UV-independent skin cancer
Taichiro Nonaka and colleagues find that AID plays a role in the development of inflammation-driven, non-UV skin cancer
Published March 14, 2016
Scientific Show StopperOncology

CD37 keeps B cell lymphoma at bay
Charlotte de Winde, Sharon Veenbergen, and colleagues demonstrate that loss of CD37 expression relieves SOCS3-mediated suppression of IL-6 signaling and supports the development of B cell lymphoma…
Published January 19, 2016
Scientific Show StopperOncology

Maintaining endometrial epithelial barrier function
Jessica Bowser and colleagues identify a mechanism by which loss of CD73 promotes endometrial cancer progression…
Published December 7, 2015
Scientific Show StopperOncology

Sleuthing out the cellular source of hepatocellular carcinoma
Xueru Mu, Regina Español-Suñer, and colleagues show that tumors in murine hepatocellular carcinoma models are derived from hepatocytes and not from other liver resident cells …
Published September 8, 2015
Scientific Show StopperOncology

Live animal imaging in the far red
Ming Zhang and colleagues developed a far-red-absorbing reporter/probe system that can be used to image live animals and overcomes imaging limitations associated with conventional systems that use lower wavelengths of light…
Published September 8, 2015
Scientific Show StopperTechnical AdvanceOncology

Cancer cells fight off stress with ATF4
Souvik Dey, Carly Sayers, and colleagues reveal that activation of heme oxygenase 1 by ATF4 protects cancer cells from ECM detachment-induced death and promotes metastasis…
Published May 26, 2015
Scientific Show StopperOncology

Smothering Von Hippel-Lindau syndrome-associated phenotypes
Ana Metelo and colleagues demonstrate that specific inhibition of HIF2a ameliorates VHL-associated phenotypes and improves survival in a zebrafish model of disease…
Published April 13, 2015
Scientific Show StopperOncology

Blazing the trail for metastasis
Jill Westcott, Amanda Prechtl, and colleagues identify an epigenetically distinct population of breast cancer cells that promotes collective invasion…
Published April 6, 2015
Scientific Show StopperOncology

Dynamic focal adhesions
Wies van Roosmalen, Sylvia E. Le Dévédec, and colleagues screen for genes that alter cancer cell migration and demonstrate that SRPK1 promotes metastasis...
Published March 16, 2015
Scientific Show StopperOncology
  • ← Previous
  • 1
  • 2
  • Next →
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts